Idera Pharmaceuticals announces financial results for the third quarter of 2009
July 20, 2017
Total revenues for the three months ended September 30, 2009 were $6.5 million compared to $7.5 million for the same period in 2008. For the nine-month period, revenues totaled $24.3 million compared to $20.2 million for the same period in 2008.
Research and development expenses for the three months ended September 30, 2009 totaled $4.3 million compared to $3.6 million for the same period in 2008. For the nine-month period, R&D expenses totaled $14.2 million compared to $11.9 million for the same period in 2008.
General and administrative expenses for the three months ended September 30, 2009 were $2.2 million compared to $2.3 million for the same period in 2008. For the nine-month period, G&A expenses totaled $6.5 million compared to $8.0 million for the same period in 2008.
As of September 30, 2009, cash, cash equivalents and investments totaled $46.1 million compared to $55.6 million at December 31, 2008.
SOURCE Idera Pharmaceuticals, Inc.